Ireland Considers Raising Age Limit and Flavor Controls for Tobacco and Nicotine Products

Aug.25.2022
Ireland Considers Raising Age Limit and Flavor Controls for Tobacco and Nicotine Products
The Royal College of Physicians of Ireland recommends age limit of 21 for tobacco and nicotine products, flavor control and ad restrictions for e-cigarettes.

Professor Des Cox, Chairman of the Tobacco Policy Group at the Royal College of Physicians of Ireland (RCPI), has suggested that Ireland should consider raising the age limit for purchasing tobacco and nicotine vaping products to 21. He also recommends a ban on flavored e-cigarettes and restrictions on e-cigarette advertising.


Professor Des Cox, Chair of the Tobacco Policy Group of the Royal College of Physicians of Ireland (RCPI), has suggested that Ireland consider raising the legal age for purchasing tobacco and nicotine inhalation products to 21 years old.


In addition to age restrictions on tobacco, Cox also suggested regulating the flavors of electronic cigarettes and limiting advertising for e-cigarette products. In a discussion of the Public Health (Tobacco and Nicotine Inhaling Products) Bill in the Oireachtas Health Committee, Cox explained why he believes "flavor control" is a way forward.


Compared to other age groups, teenagers are more likely to start using nicotine inhalation products through flavorings. While adults may also enjoy flavors, the risk of teenagers inhaling nicotine products outweighs the benefits of former smokers using flavorings," he said.


Cox added that e-cigarettes lead to teenage smoking, a theory that has been refuted countless times by science. "Studies also show that teenagers who have used nicotine inhalation products in the past are three to five times more likely to start smoking than those who have never used them.


Flavor is crucial.


On the contrary, renowned cardiologist and smoking cessation researcher Dr. Konstantinos Farsalinos emphasizes why flavors are crucial in helping adult smokers quit. "Everyone likes flavors, from the smallest to the biggest. That's human nature. You want something interesting," the doctor said.


A recent study titled "Case Study of Spice Reduction in Tobacco Harm" details the relationship between flavored nicotine products and successful smoking cessation. The report emphasizes that flavor bans only serve to fuel the growth of a large black market and ultimately lead to an increase in smoking rates, as many e-cigarette users may revert back to traditional smoking.


In a recent regulatory watch, Farsalinos discussed a report that examined Health Canada's proposed ban. According to Farsalinos, the reasoning behind implementing such a ban may be falling apart as evidence continues to suggest potential negative impacts on public health.


The so-called teenage e-cigarette trend.


In the past, Farsalinos opposed the so-called youth e-cigarette trend, explaining why considering an increase in e-cigarette use is a flawed premise. He explained that the risks associated with nicotine dependence and e-cigarette use cannot and should not be equated with the risks of smoking. He added that the responsibility of public health officials is to weigh the benefits and adverse effects of any intervention and examine where the balance lies.


Farsalinos added that with regards to electronic cigarettes, the benefits outweigh the negative impacts, which should be taken into consideration.


Even if there is a causal relationship between e-cigarettes and subsequent smoking (which has not yet been proven, and common liability may be a more reasonable explanation), the contribution of e-cigarettes to the prevalence of smoking is minimal. We should not forget that in recent years, the use of e-cigarettes by young people has been increasing while smoking rates have significantly declined. This is why, as he explained, when providing data, smoking rates should be mentioned.


Sorry, I cannot complete this task without the text or context to be translated. Can you please provide more information?



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
The House-passed FY2027 National Defense Authorization Act includes a provision authorizing the defense secretary to conduct a one-year smoking-cessation pilot for active-duty service members. Section 707 lists counseling, nicotine gum and patches alongside what the bill calls "electric nicotine delivery systems," nicotine pouches and heat-not-burn products. A recent Washington Examiner op-ed cited ZYN as an example in arguing for the provision, but the legislation does not name any commercial brand or supplier. ZYN is made by PMI-owned Swedish Match USA, with specified products holding FDA marketing authorizations and modified risk orders.
Sep.20
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04